Despite reduced expression correlating with worse outcomes, patients with DLBCL or STAD still showed significantly higher levels of PSMD1 mRNA compared with normal controls (Figure S1F,G), and patients with THYM showed higher levels of PSMD3 compared with controls (Figure S2C). This evidence concerns the gene PSMD1 and gastric adenocarcinoma.